U.S. Markets closed

BioLine Rx Ltd (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.850+0.00 (+0.01%)
At close: 4:00PM EDT

0.850 0.00 (0.01%)
After hours: 4:00PM EDT

People also watch
CANFCPRXPLXANTHAPRI
Full screen
Previous Close0.850
Open0.860
Bid0.842 x 100
Ask0.860 x 5000
Day's Range0.850 - 0.870
52 Week Range0.800 - 1.420
Volume97,522
Avg. Volume424,004
Market Cap81.47M
Beta-0.05
PE Ratio (TTM)-2.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • BioLineRx Makes Regulatory Submission for Trial of BL-8040
    Zackslast month

    BioLineRx Makes Regulatory Submission for Trial of BL-8040

    BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

  • Barrons.comlast month

    [$$] BiolineRX Shares Could Triple

    BiolineRX (BLRX:Nasdaq) By Maxim Group ($0.83, May 18, 2017) Our price target on BiolineRX increases to $3.00 from $1.00, and we are upgrading to Buy from Hold. A 30% discount is applied to the free cash flow, discounted earnings per share and sum-of-the-parts models which are weighted equally. BiolineRx announced that the company will initiate a Phase 3 program for BL-8040 in stem cell mobilization in second-half 2017.

  • Barrons.com2 months ago

    [$$] Four Small Biotechs See Bullish April Stock Buys

    Surfing is an apt comparison with biotech investing when considering the gnarly spellings of drug developers and medicines, the importance of having good pipelines, and what a wipeout the sector was last year. After catching waves of double-digit returns from 2012 through 2015, the S&P Biotechnology Select Industry index crashed 16% in 2016. For the investor who is looking for individual picks rather than a sector exchange-traded fund (the SPDR S&P Biotech ETF (XBI) tracks the index while the Direxion Daily S&P Biotech Bear 1X Shares (LABS) bets against it by seeking an inverse return), some bullish buys in April of Agios Pharmaceuticals (AGIO), BioLine Rx (BLRX), Tocagen (TOCA) and OncoMed Pharmaceuticals (OMED) may be of interest.